arrow
R

Robyn P.M. Saw

the university of sydney
H指数:85
被引数:6.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of Immediate Therapeutic Lymph Node Dissection Instead of Index Lymph Node After Neoadjuvant Checkpoint Inhibitors: Lessons Learned from the PRADO Trial

新辅助免疫检查点抑制剂治疗后立即进行非原发淋巴结清扫的预测因素:PRADO试验的经验教训

2026-10-240
PRE
Effectiveness of a stepped-care model to address fear of cancer recurrence in patients with early-stage melanoma: results at 6- and 12-month follow-up

针对早期黑色素瘤患者癌症复发恐惧的阶梯护理模式有效性:6个月和12个月随访结果

2025-12-270
PRE
Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial

PET/CT在黑色素瘤盆腔淋巴结转移诊断中的准确性:一项前瞻性、随机、III期“评价腹股沟淋巴结清扫范围对转移性黑色素瘤影响(EAGLE-FM)”试验的亚组分析

2025-11-120
PRE
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

III期黑色素瘤辅助治疗中的动态复发风险预测工具

2025-09-120
PRE
Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node–positivity in melanoma patients

淋巴闪烁显像后的结节放射性作为黑色素瘤患者哨兵淋巴结阳性的指导

2025-06-090
OA
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

原发性皮肤黑色素瘤患者哨兵淋巴结阳性风险预测工具的全球适用性

2025-06-010
PRE
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort

纵向分析揭示了在III期BRAF突变黑色素瘤队列中,对新辅助治疗有应答者的组织病理学特征发生动态变化。

2025-05-100
PRE
Cartilage Resection in the Surgical Management of Ear Melanoma

耳黑色素瘤手术管理中的软骨切除术

2025-04-280
OA
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance (vol 40, pg 88, 2022)

多组学分析:检查点抑制剂治疗的黑色素瘤:识别应答和耐药的预测因子,以及生物学不一致性的标志物(卷40,页88,2022)

2025-02-010
PRE
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo

个性化反应导向手术和辅助治疗对III期黑色素瘤新辅助免疫治疗后生存的影响: PRADO和OpACIN-neo的3年数据比较

2025-01-010
PRE
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

头颈部皮肤黑色素瘤和其他部位黑色素瘤的临床病理特征和治疗结果的比较: 全身治疗的意义

2025-01-011
OAAI
Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study
2024-12-180
PRE
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
CANCER
IF5.1
2024-11-101
OA
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas

前哨淋巴结阳性在线风险计算器对T1和T2黑色素瘤患者管理的影响

2024-07-030
PRE
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600-mutant可切除黑色素瘤的新辅助治疗: 随机2期NeoTrio试验

2024-06-213
OAAI